IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

Verona Pharma PLC - clinical-stage biopharmaceutical company - Pretax loss in third quarter ended ...

Alliance News 29 October, 2020 | 7:09PM
Email Form

Verona Pharma PLC - clinical-stage biopharmaceutical company - Pretax loss in third quarter ended September 30 widens to USD22.2 million from USD15.7 million a year earlier. For nine-months to September, loss stretches to USD47.1 million from USD38.7 million.

Current stock price: 51.00 pence

Year-to-date change: down 18%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Verona Pharma PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies